Abstract
Clonal hematopoiesis of indeterminate potential (CHIP), whereby somatic mutations in hematopoietic stem cells confer a selective advantage and drive clonal expansion, not only correlates with age but also confers increased risk of morbidity and mortality. Here, we leverage genetically predicted traits to identify factors that determine CHIP clonal expansion rate. We used the passenger-approximated clonal expansion rate method to quantify the clonal expansion rate for 4,370 individuals in the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) cohort and calculated polygenic risk scores for DNA methylation aging, inflammation-related measures and circulating protein levels. Clonal expansion rate was significantly associated with both genetically predicted and measured epigenetic clocks. No associations were identified with inflammation-related lab values or diseases and CHIP expansion rate overall. A proteome-wide search identified predicted circulating levels of myeloid zinc finger 1 and anti-Müllerian hormone as associated with an increased CHIP clonal expansion rate and tissue inhibitor of metalloproteinase 1 and glycine N-methyltransferase as associated with decreased CHIP clonal expansion rate. Together, our findings identify epigenetic and proteomic patterns associated with the rate of hematopoietic clonal expansion.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
Data availability
WGS data for individuals in the TOPMed cohort and the CHIP variant call sets are available through restricted access from the dbGaP TOPMed Exchange Area available to TOPMed investigators to protect patient privacy. Individuals who want to apply for access to TOPMed data should follow the steps listed online (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/about.html#request-controlled). Summary statistics for the measures of DNA methylation aging are available at https://datashare.ed.ac.uk/handle/10283/3645 and summary statistics for the four significant proteins are available at www.omicspred.org. All other data supporting the findings of the study are available from the authors upon request.
Code availability
Code developed to call passenger mutations using the Mutect2 WDL pipeline is available at https://dockstore.org/workflows/github.com/broadinstitute/gatk/mutect2:4.1.8.1?tab=info. Code on passenger variant filtering and quality control is available at https://github.com/weinstockj/passenger_count_variant_calling. Code to calculate PRSs is available for PRScs at https://github.com/getian107/PRScs and PRScsx at https://github.com/getian107/PRScsx.
References
Heuser, M., Thol, F. & Ganser, A. Clonal hematopoiesis of indeterminate potential. Dtsch. Ärztebl. Int. 113, 317–322 (2016).
Argüelles, O. C. et al. Clonal hematopoiesis associated mutations, cardiovascular events, and all-cause death among patients with acute myeloid leukemia. J. Am. Coll. Cardiol. 75, 671 (2020).
Miller, P. G. et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood 139, 357–368 (2022).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Bick, A. G. et al. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Sci. Rep. 12, 577 (2022).
Jaiswal, S. et al. Clonal hematopoiesis and risk for atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat. Commun. 7, 12484 (2016).
Bowman, R. L., Busque, L. & Levine, R. L. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell 22, 157–170 (2018).
Uddin, M. M. et al. Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. Immun. Ageing 19, 23 (2022).
Watson, C. J. et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367, 1449–1454 (2020).
Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219–1226 (2020).
van Deuren, R. C. et al. Expansion of mutation-driven haematopoietic clones is associated with insulin resistance and low HDL-cholesterol in individuals with obesity. Preprint at bioRxiv https://doi.org/10.1101/2021.05.12.443095 (2021).
Park, S. J. & Bejar, R. Clonal hematopoiesis in aging. Curr. Stem Cell Rep. 4, 209–219 (2018).
Nachun, D. et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell 20, e13366 (2021).
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
Weinstock, J. S. et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature 616, 755–763 (2023).
Bick, A. G. et al. Inherited causes of clonal hematopoiesis in 97,691 TOPMed whole genomes. Nature 586, 763–768 (2020).
Vlasschaert, C. et al. A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets. Blood 141, 2214–2223 (2023).
Osorio, F. G. et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 25, 2308–2316 (2018).
Mitchell, E. et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 606, 343–350 (2022).
Williams, N. et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature 602, 162–168 (2022).
Field, A. E. et al. DNA methylation clocks in aging: categories, causes, and consequences. Mol. Cell 71, 882–895 (2018).
McCartney, D. L. et al. Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome Biol. 22, 194 (2021).
Lu, A. T. et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging 11, 303–327 (2019).
Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging 10, 573–591 (2018).
Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49, 359–367 (2013).
Robertson, N. A. et al. Age-related clonal haemopoiesis is associated with increased epigenetic age. Curr. Biol. 29, R786–R787 (2019).
SanMiguel, J. M. et al. Distinct tumor necrosis factor α receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 12, 2763–2773 (2022).
Marnell, C. S., Bick, A. & Natarajan, P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J. Mol. Cell. Cardiol. 161, 98–105 (2021).
Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124–131 (2020).
Kristinsson, S. Y. et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J. Clin. Oncol. 29, 2897–2903 (2011).
Cho, R. H., Sieburg, H. B. & Muller-Sieburg, C. E. A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 111, 5553–5561 (2008).
Franceschi, C. et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908, 244–254 (2000).
Gong, Y. et al. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS ONE 8, e77366 (2013).
Song, G. et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK–PI3K/AKT and MAPK pathway. J. Exp. Clin. Cancer Res. 35, 148 (2016).
Schoeps, B. et al. TIMP1 triggers neutrophil extracellular trap formation in pancreatic cancer. Cancer Res. 81, 3568–3579 (2021).
Pesta, M. et al. Prognostic significance of TIMP-1 in mon-small cell lung cancer. Anticancer Res. 31, 4031–4038 (2011).
Song, Y. H., Shiota, M., Kuroiwa, K., Naito, S. & Oda, Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod. Pathol. 24, 1272–1280 (2011).
DebRoy, S. et al. A novel tumor suppressor function of glycine N-methyltransferase is independent of its catalytic activity but requires nuclear localization. PLoS ONE 8, e70062 (2013).
La Marca, A. & Volpe, A. The anti-Müllerian hormone and ovarian cancer. Hum. Reprod. Update 13, 265–273 (2007).
Jung, S. et al. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. Int. J. Cancer 142, 262–270 (2018).
Brix, D. M., Bundgaard Clemmensen, K. K. & Kallunki, T. Zinc finger transcription factor MZF1—a specific regulator of cancer invasion. Cells 9, 223 (2020).
Vishwamitra, D. et al. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK+ T-cell lymphoma. Mol. Cancer 14, 53 (2015).
Perrotti, D. et al. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol. Cell. Biol. 15, 6075–6087 (1995).
Cook, E. K., Luo, M. & Rauh, M. J. Clonal hematopoiesis and inflammation: partners in leukemogenesis and comorbidity. Exp. Hematol. 83, 85–94 (2020).
Avagyan, S. et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374, 768–772 (2021).
Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137–1146 (2007).
Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature 590, 290–299 (2021).
Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 17, 1520–1528 (2007).
Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. Nat. Genet. 54, 573–580 (2022).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Lu, A. T. et al. GWAS of epigenetic aging rates in blood reveals a critical role for TERT. Nat. Commun. 9, 387 (2018).
Xu, Y. et al. An atlas of genetic scores to predict multi-omic traits. Nature 616, 123–131 (2023).
Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822–1832 (2019).
Trynka, G. et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat. Genet. 43, 1193–1201 (2011).
Aterido, A. et al. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann. Rheum. Dis. 78, 355–364 (2019).
Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979–986 (2015).
Robertson, C. C. et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nat. Genet. 53, 962–971 (2021).
Barnes, C. L. K. et al. Contribution of common risk variants to multiple sclerosis in Orkney and Shetland. Eur. J. Hum. Genet. 29, 1701–1709 (2021).
Warren, H. R. et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat. Genet. 49, 403–415 (2017).
Han, Y. et al. Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma. Nat. Commun. 11, 1776 (2020).
Matsunaga, H. et al. Transethnic meta-analysis of genome-wide association studies identifies three new loci and characterizes population-specific differences for coronary artery disease. Circ. Genom. Precis. Med. 13, e002670 (2020).
Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776 (2019).
Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457–1464 (2015).
Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730–738 (2013).
Cai, L. et al. Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study. Sci. Data 7, 393 (2020).
Pardiñas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389 (2018).
Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat. Neurosci. 22, 343–352 (2019).
Otowa, T. et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol. Psychiatry 21, 1391–1399 (2016).
Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
Tsoi, L. C. et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat. Commun. 8, 15382 (2017).
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
Acknowledgements
WGS for the TOPMed program was supported by the NHLBI. Centralized read mapping and genotype calling, along with variant quality metrics and filtering, were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity quality control and general study coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We thank the study participants who provided biological samples and data for TOPMed. The full study-specific acknowledgments are included in the Supplementary Acknowledgements. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the NHLBI, the National Institutes of Health or the US Department of Health and Human Services. S.J. is supported by the Burroughs Wellcome Foundation Career Award for Medical Scientists, Foundation Leducq (TNE-18CVD04), the Ludwig Center for Cancer Stem Cell Research, the American Society of Hematology Scholar Award, the NIH Director’s New Innovator Award (DP2-HL157540) and a Leukemia and Lymphoma Society Discovery Grant. A.G.B. is supported by a Burroughs Wellcome Foundation Career Award for Medical Scientists, the NIH Director’s Early Independence Award (DP5-OD029586) and the Pew-Stewart Scholar for Cancer Research award, supported by the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust.
Author information
Authors and Affiliations
Contributions
T.M.M. and M.A.R. conceptualized and designed the study, performed the analyses and wrote the manuscript. Y.P. performed analyses. A.G.B., J.S.W. and S.J. conceptualized PACER and contributed to the study design. J.S.W. performed somatic variant calling. A.G.B. supervised the work and contributed to the drafting of the manuscript. D.C.N., K.D.T., X.G., A.R.S., J.R.O., E.E.K., R.J.F.L., S.R., B.E.C., B.M.P., J.C.B., J.A.B., E.K.S., J.H.Y., M.H.C., D.L.D., D.L., A.D.J., R.A.M., L.R.Y., S.R.H., N.L.S., K.L.W., L.M.R., A.P.C., J.I.R., S.S.R., A.W.M., C.C.G., Y.I.C., W.L., M.B.S., D.R., C.K., P.L.A., P.D., T.W.B., A.V.S., A.P.R. and the NHLBI TOPMed Consortium contributed to sequencing and phenotyping of the included NHLBI TOPMed cohorts. All authors read, revised and approved the manuscript.
Corresponding author
Ethics declarations
Competing interests
S.J. is on advisory boards for Novartis, AVRO Bio and Roche Genentech, reports speaking fees and honorarium from GSK and is on the scientific advisory board of Bitterroot Bio. P.N. reports grants support from Amgen, AstraZeneca, Apple, Novartis and Boston Scientific, is a paid consultant for Apple, AstraZeneca, Novartis, Genentech and Blackstone Life Sciences and has spousal employment at Vertex, all unrelated to the present work. S.J., A.G.B. and P.N. are paid consultants for Foresite Labs and cofounders, equity holders and scientific advisory board members of TenSixteen Bio. Stanford University has filed a patent application for the use of PACER to identify therapeutic targets, on which S.J., A.G.B. and J.S.W. are listed as inventors (US patent 63/141,333). The patent has been licensed to TenSixteen Bio. A.S. is an employee of Regeneron Pharmaceuticals. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson and Johnson. E.S. receives grant support from Bayer and GSK. J.Y. and D.D. receive grant support from Bayer. M.C. receives grant support from Bayer and GSK and consulting and speaking fees from Illumina and AstraZeneca. S.S.R. and L.M.R. are paid consultants for Westat, the Administrative Coordinating Center for the NHLBI TOPMed program. The remaining authors declare no competing interests.
Peer review
Peer review information
Nature Aging thanks Siddhartha Kar, Jennifer Kwan and Kristina Kirschner for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Description of CHIP cohort characteristics.
A density plot displaying the distribution of driver gene VAF across the cohort stratified by driver gene as well as the overall driver gene count across the cohort.
Extended Data Fig. 2 Epigenetic aging correlation measures.
Correlation in methylation measures. (a) Correlation matrix within measured epigenetic aging data. (b) Correlation matrix within predicted epigenetic aging data. (c) Box plot showing correlation between calculated PRS (n = 297 individuals) (grouped into quartiles) and z-scored measured methylation data. Color denotes a significant association between measured and PRS data. The center line is the median value, with the bounds of the box representing the first through third quartiles and the whiskers representing the minimum and maximum while any remaining points are outliers.
Extended Data Fig. 3 Full regression results for inflammation analyses.
Linear regressions of clonal expansion rate with inflammation (full results). (a) Heat map showing associations between clonal expansion rate and PRS for inflammation-related proteins from the Somalogic database stratified by CHIP gene. Significance and direction of effect are denoted by the color of the box. (b) Heat map showing associations between clonal growth and PRS for inflammation-related phenotypes. Significance and direction of effect are denoted by the color of the box.
Extended Data Fig. 4 Gene-specific circulating protein regression results.
Linear regressions of clonal expansion rate with predicted protein levels in CHIP gene-specific analyses. Volcano plots showing significantly associated protein PRS from the Somalogic database. Colored points are statistically significant. The color of the point shows the direction of the effect (blue = negative, red = positive). To account for multiple testing, we used a Bonferroni corrected p-value of 2.3 × 10−5. (a) DNMT3A-specific CHIP (b) TET2-specific CHIP (c) SRSF2/SF3B1/U2AF1-specific CHIP.
Extended Data Fig. 5 Sex-stratified circulating protein regression results.
Linear regression analyses of clonal expansion rate with Somalogic protein PRS stratified by biological sex (n = 4,370 individuals). To account for multiple testing, we used a Bonferroni corrected p-value of 0.01.
Extended Data Fig. 6 Full results of GSEA analyses.
Hallmark pathways in Gene Set Enrichment Analysis (GSEA). (a) Heat map showing the pathways most implicated in both overall CHIP and gene-specific CHIP. Color denotes the direction of the association. GSEA is a statistical functional enrichment analysis. (b) Protein PRSs contributing to the hallmark pathways most strongly associated with clonal expansion rate. Color denotes the direction of the association.
Extended Data Fig. 7 Gene-specific GSEA results.
Gene Set Enrichment Analysis (GSEA) results for CHIP gene-specific analyses. (a) Pathways implicated in the associations between clonal expansion rate and circulating protein PRS in DNMT3A-specific CHIP. (b) TET2-specific CHIP. (c) Pearson’s correlation test between pathways implicated in DNMT3A & TET2-specific CHIP. The translucent error bars around the linear regression line represent 95% confidence intervals.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mack, T.M., Raddatz, M.A., Pershad, Y. et al. Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate. Nat Aging 4, 1043–1052 (2024). https://doi.org/10.1038/s43587-024-00647-7
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43587-024-00647-7
This article is cited by
-
Inflammageing and clonal haematopoiesis interplay and their impact on human disease
Nature Reviews Molecular Cell Biology (2026)
-
Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases
Military Medical Research (2025)
-
Clonal hematopoiesis: elements associated with clonal expansion and diseases
Blood Research (2025)


